126 related articles for article (PubMed ID: 34111425)
1. Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.
Zhao C; Yang D; Ye Y; Chen Z; Sun T; Zhao J; Zhao K; Lu N
Biochem Pharmacol; 2021 Aug; 190():114648. PubMed ID: 34111425
[TBL] [Abstract][Full Text] [Related]
2. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
4. Pim2 is important for regulating DNA damage response in multiple myeloma cells.
Ramachandran J; Santo L; Siu KT; Panaroni C; Raje N
Blood Cancer J; 2016 Aug; 6(8):e462. PubMed ID: 27564460
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Ha DH; Min A; Kim S; Jang H; Kim SH; Kim HJ; Ryu HS; Ku JL; Lee KH; Im SA
Sci Rep; 2020 Jun; 10(1):9930. PubMed ID: 32555285
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
7. MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Yi J; Liu C; Tao Z; Wang M; Jia Y; Sang X; Shen L; Xue Y; Jiang K; Luo F; Liu P; Cheng H
EBioMedicine; 2019 May; 43():225-237. PubMed ID: 30898650
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability.
Kim DY; Yun H; You JE; Lee JU; Kang DH; Ryu YS; Koh DI; Jin DH
Exp Cell Res; 2024 May; 438(1):114036. PubMed ID: 38614421
[TBL] [Abstract][Full Text] [Related]
9. WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.
Burdova K; Storchova R; Palek M; Macurek L
Cells; 2019 Oct; 8(10):. PubMed ID: 31619012
[TBL] [Abstract][Full Text] [Related]
10. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
11. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
13. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC
Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Pessetto ZY; Yan Y; Bessho T; Natarajan A
Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation.
Hirai T; Shirai H; Fujimori H; Okayasu R; Sasai K; Masutani M
Cancer Sci; 2012 Jun; 103(6):1045-50. PubMed ID: 22404155
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
17. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor re‑sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
Wu J; Xiao S; Yuan M; Li Q; Xiao G; Wu W; Ouyang Y; Huang L; Yao C
Mol Med Rep; 2019 Jan; 19(1):75-84. PubMed ID: 30431088
[TBL] [Abstract][Full Text] [Related]
19. Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
McDonald ES; Mankoff J; Makvandi M; Chu W; Chu Y; Mach RH; Zeng C
Biochem Biophys Res Commun; 2017 May; 486(3):788-795. PubMed ID: 28347815
[TBL] [Abstract][Full Text] [Related]
20. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]